Leuprolide Acetate Depot for Injection 3.75 mg
LEUPOLIEVA DEPOT 3.75 MG (Leuprolide Acetate Depot for Injection 3.75 mg) is a prescription hormonal medicine containing Leuprolide Acetate 3.75 mg in a long-acting depot formulation. Leuprolide belongs to the Gonadotropin-Releasing Hormone (GnRH) Agonist class and is used to suppress the production of sex hormones.
When administered continuously, Leuprolide initially stimulates the pituitary gland and subsequently reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a significant reduction in testosterone production in males and estrogen production in females.
LEUPOLIEVA DEPOT 3.75 MG may be used in the management of advanced prostate cancer, endometriosis, uterine fibroids, and other approved hormone-dependent conditions, depending on the patient's clinical condition and the prescribing information applicable to the product.
The depot formulation is designed to provide sustained release of Leuprolide Acetate, helping maintain hormonal suppression over the prescribed treatment interval.
The injection should be prepared and administered by a qualified healthcare professional.
LEUPOLIEVA DEPOT 3.75 MG is commonly used for:
Advanced Prostate Cancer
Hormone-Dependent Prostate Cancer
Endometriosis
Uterine Fibroids
Hormonal Suppression Therapy
Androgen Deprivation Therapy
Hormone-Dependent Conditions
Patients receiving Leuprolide therapy require regular monitoring of treatment response and relevant clinical parameters.
View Details
Leuprolide Acetate Depot for Injection 11.25 mg
LEUPOLIEVA DEPOT (Leuprolide Acetate Depot for Injection 11.25 mg) is a prescription hormonal medicine containing Leuprolide Acetate 11.25 mg in a long-acting depot formulation. Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist used in the management of hormone-dependent conditions and certain cancers.
Leuprolide initially stimulates the pituitary gland to release gonadotropins. With continued administration, it suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a significant reduction in testosterone levels in males and estrogen levels in females.
LEUPOLIEVA DEPOT 11.25 MG is commonly used in the management of advanced prostate cancer and may also be prescribed for certain hormone-dependent conditions such as endometriosis and uterine fibroids, depending on the approved indication and treatment plan.
The depot formulation is designed to provide sustained release of Leuprolide Acetate over an extended period, reducing the need for frequent administration.
The medicine is administered by a qualified healthcare professional according to the prescribed treatment schedule.
LEUPOLIEVA DEPOT is commonly used for:
Advanced Prostate Cancer
Hormone-Dependent Prostate Cancer
Endometriosis
Uterine Fibroids
Hormonal Suppression Therapy
Androgen Deprivation Therapy
Oncology Treatment Programs
Patients receiving Leuprolide therapy require regular monitoring of treatment response, hormone levels, and relevant clinical parameters.
View Details
Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL
DOXLIEVA-L 50 MG (Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL) is a prescription anticancer medicine containing Doxorubicin Hydrochloride 50 mg in a liposomal formulation. It belongs to the Anthracycline class of anticancer medicines and is used in the treatment of several cancers.
The liposomal formulation encapsulates doxorubicin within microscopic lipid particles called liposomes. This formulation alters the distribution of the medicine in the body and allows doxorubicin to reach tumor tissues while potentially reducing some of the toxicity associated with conventional doxorubicin.
Doxorubicin works primarily by interfering with DNA replication and repair and by inhibiting topoisomerase II, an enzyme required for cancer cell division. It can also generate free radicals that contribute to cancer cell damage. These actions inhibit the growth and multiplication of cancer cells.
DOXLIEVA-L 50 MG may be used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma in combination therapy, and certain other cancers, depending on the approved indication and treatment protocol.
The medicine is administered by intravenous infusion under the supervision of qualified healthcare professionals experienced in oncology treatment.
DOXLIEVA-L 50 MG is commonly used in:
Ovarian Cancer
AIDS-Related Kaposi's Sarcoma
Multiple Myeloma in Combination Therapy
Advanced Malignancies
Selected Solid Tumors
Combination Oncology Treatment Protocols
Patients receiving liposomal doxorubicin require regular monitoring of blood counts, liver function, cardiac health, and overall clinical condition.
View Details
Megestrol Acetate Oral Suspension USP 40 mg/ml
MEGESLIEVA 40 MG (Megestrol Acetate Oral Suspension USP 40 mg/mL) is a prescription medicine containing Megestrol Acetate 40 mg/mL, a synthetic progestin (progesterone derivative) used in the management of certain cancers and conditions associated with severe weight loss and loss of appetite. It belongs to the Hormonal Therapy class of medicines and is commonly prescribed under the supervision of an oncologist or other qualified healthcare professional.
Megestrol Acetate works by influencing hormone-sensitive tissues and helping regulate appetite. In oncology, it is used in selected hormone-responsive cancers, while it is also widely prescribed to stimulate appetite and promote weight gain in patients experiencing cancer-related cachexia or other chronic illnesses associated with significant weight loss.
MEGESLIEVA 40 MG Oral Suspension is commonly prescribed for the treatment of advanced breast cancer, advanced endometrial (uterine) cancer, cancer-related anorexia, cachexia (weight loss syndrome), and appetite loss in selected patients.
The oral suspension formulation is particularly suitable for patients who have difficulty swallowing tablets or capsules, providing convenient administration and accurate dose adjustment.
MEGESLIEVA 40 MG is commonly used for:
Advanced Breast Cancer
Advanced Endometrial Cancer
Cancer-Related Cachexia
Loss of Appetite (Anorexia)
Weight Loss Associated with Chronic Illness
Nutritional Support in Oncology Patients
Hormonal Therapy
Supportive Cancer Care
Manufactured according to stringent pharmaceutical quality standards, MEGESLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Megestrol Acetate therapy should undergo regular medical evaluations to monitor treatment response and overall health.
View Details
Apalutamide Tablets 60 mg
APALIEVA 60 MG (Apalutamide Tablets 60 mg) is a prescription anticancer medicine containing Apalutamide 60 mg, an oral androgen receptor inhibitor used in the treatment of specific types of prostate cancer. Apalutamide belongs to a class of medicines known as Androgen Receptor (AR) Inhibitors, which help slow the growth and spread of prostate cancer cells by blocking the action of male hormones (androgens).
Prostate cancer cells often rely on androgens, such as testosterone, to grow and multiply. Apalutamide works by binding to androgen receptors, preventing these hormones from activating cancer cells. This helps inhibit cancer cell growth, delay disease progression, and improve treatment outcomes.
APALIEVA 60 MG is commonly prescribed for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is generally used in combination with androgen deprivation therapy (ADT) as recommended by an oncologist or urologist.
The medicine is taken orally and should be used only under the supervision of a qualified healthcare professional experienced in cancer treatment.
APALIEVA 60 MG is commonly used for:
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Advanced Prostate Cancer
Hormone-Sensitive Prostate Cancer
Androgen Receptor-Positive Prostate Cancer
Long-Term Prostate Cancer Management
Combination Hormonal Therapy
Oncology Treatment Programs
Manufactured according to stringent pharmaceutical quality standards, APALIEVA 60 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Apalutamide therapy require regular monitoring of their clinical condition and laboratory parameters to ensure safe and effective treatment.
View Details
Empagliflozin Tablets 25mg
EMPALIEVA 25 MG (Empagliflozin Tablets 25 mg) is a prescription medicine containing Empagliflozin 25 mg, an oral antidiabetic medication belonging to the Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor class. It is primarily used to improve blood sugar control in adults with Type 2 Diabetes Mellitus and is also associated with cardiovascular and kidney health benefits in appropriate patients.
Empagliflozin works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing the elimination of excess glucose through urine. This helps lower blood glucose levels independently of insulin while also supporting modest weight reduction and blood pressure control in many patients.
EMPALIEVA 25 MG is commonly prescribed along with a healthy diet and regular exercise for adults with Type 2 Diabetes Mellitus. It may be used alone or in combination with other antidiabetic medicines as recommended by a healthcare professional.
The medicine is taken orally and should be used exactly as prescribed by a qualified healthcare provider.
EMPALIEVA 25 MG is commonly used for:
Type 2 Diabetes Mellitus
Blood Glucose Control
Cardiovascular Risk Reduction in Eligible Patients
Heart Failure Management (as advised by a physician)
Chronic Kidney Disease Management (in appropriate patients)
Combination Antidiabetic Therapy
Long-Term Diabetes Management
Manufactured according to stringent pharmaceutical quality standards, EMPALIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Empagliflozin therapy should undergo regular monitoring of blood glucose levels, kidney function, and overall health during treatment.
View Details
Vincristine Sulphate Injection USP 1 mg
VINLIEVA 1 MG (Vincristine Sulphate Injection USP 1 mg) is a prescription anticancer medicine containing Vincristine Sulphate 1 mg, a chemotherapy agent belonging to the Vinca Alkaloid class of anticancer drugs. Vincristine is widely used in the treatment of various hematological malignancies and solid tumors by interfering with cancer cell division and preventing tumor growth.
Vincristine works by binding to tubulin proteins and preventing the formation of microtubules, which are essential for cell division. This disruption of mitosis inhibits the multiplication of rapidly growing cancer cells and ultimately leads to their destruction.
VINLIEVA 1 MG is commonly prescribed for the treatment of Acute Lymphoblastic Leukemia (ALL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Wilms' Tumor, Neuroblastoma, Rhabdomyosarcoma, and other cancers. It is frequently administered as part of combination chemotherapy regimens.
The medicine is administered intravenously (IV) only under the supervision of qualified healthcare professionals experienced in oncology treatment. Vincristine must never be administered by the intrathecal route, as this can be fatal.
VINLIEVA 1 MG is commonly used for:
Acute Lymphoblastic Leukemia (ALL)
Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)
Wilms' Tumor
Neuroblastoma
Rhabdomyosarcoma
Multiple Myeloma (selected treatment protocols)
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, VINLIEVA 1 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Vincristine therapy require regular monitoring of blood counts, neurological function, and overall clinical condition throughout treatment.
Due to its proven efficacy in combination chemotherapy, VINLIEVA 1 MG remains an essential medicine in modern oncology practice.
View Details
Celecoxib Mouth Dissolving Tablets 200 mg
BREXLIEVA 200 MG (Celecoxib Mouth Dissolving Tablets 200 mg) is a prescription medication containing Celecoxib 200 mg, a non-steroidal anti-inflammatory drug (NSAID) belonging to the Selective COX-2 Inhibitor class. It is formulated as a mouth dissolving tablet (MDT), allowing convenient administration without the need for swallowing conventional tablets.
Celecoxib works by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme, which plays a key role in the production of prostaglandins responsible for pain, inflammation, and swelling. By reducing prostaglandin production, Celecoxib helps relieve pain and inflammation while having a lower risk of stomach irritation compared to some traditional NSAIDs.
BREXLIEVA 200 MG is commonly prescribed for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, musculoskeletal disorders, and inflammatory conditions. It may also be used as part of supportive care in selected clinical situations under medical supervision.
The mouth dissolving formulation offers ease of administration, especially for patients who experience difficulty swallowing conventional tablets.
BREXLIEVA 200 MG is commonly used for:
Osteoarthritis
Rheumatoid Arthritis
Ankylosing Spondylitis
Acute Pain Management
Musculoskeletal Pain
Joint Pain and Inflammation
Post-Operative Pain
Chronic Inflammatory Conditions
Manufactured according to stringent pharmaceutical quality standards, BREXLIEVA 200 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients using Celecoxib should follow medical advice carefully and attend routine follow-up evaluations when required.
View Details
Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Enzalutamide Tablets 160mg
ENZALIEVA Enzalutamide Tablets 160mg is an advanced anticancer medicine used for the treatment of prostate cancer in adult patients. It contains Enzalutamide, a powerful androgen receptor inhibitor that helps slow down the growth and spread of prostate cancer cells. This medicine is commonly prescribed by oncologists as part of hormone therapy for patients suffering from advanced or metastatic prostate cancer.
Prostate cancer is one of the most common cancers affecting men worldwide. Cancer cells in the prostate often depend on male hormones called androgens, especially testosterone, for growth and survival. Enzalutamide works by blocking the action of these hormones, helping reduce the ability of cancer cells to grow and multiply. Due to its targeted mechanism of action, ENZALIEVA is widely used in modern oncology treatment protocols for prostate cancer management.
ENZALIEVA Enzalutamide Tablets 160mg is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine is commonly recommended in patients with:
Metastatic castration-resistant prostate cancer (mCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC)
This anticancer medicine is usually prescribed when prostate cancer continues to progress despite reduced testosterone levels or hormonal treatment. Doctors may use ENZALIEVA alone or in combination with other therapies depending on the patient’s condition, cancer stage, and overall treatment plan.
Enzalutamide Tablets are known for helping improve disease management by delaying cancer progression and supporting overall treatment outcomes. The medicine has become an important part of prostate cancer therapy due to its effectiveness in controlling androgen receptor activity, which plays a major role in prostate cancer growth.
Patients should use this medicine strictly under the supervision of qualified healthcare professionals. Proper medical monitoring and regular health checkups are important during treatment to ensure better response and patient safety.
View Details
Etoposide Injection IP 100 MG
VEPELIEVA Etoposide Injection IP 100MG is a widely used anticancer chemotherapy medicine formulated for the treatment of different types of cancers. It contains Etoposide, an effective oncology medicine that helps slow down or stop the growth of cancer cells in the body. This injection is commonly used in hospitals, cancer treatment centers, and oncology clinics under the supervision of experienced healthcare professionals.
Etoposide belongs to a class of medicines known as topoisomerase inhibitors. It works by interfering with the DNA replication process of rapidly growing cancer cells. By damaging the DNA of these abnormal cells, the medicine helps prevent their growth and spread. Due to its effectiveness in chemotherapy treatment protocols, Etoposide Injection IP 100MG is commonly prescribed in combination with other anticancer medicines for better treatment outcomes.
VEPELIEVA is manufactured under high pharmaceutical quality standards to ensure safety, purity, and effectiveness. The medicine is designed to meet the requirements of modern oncology treatment and is trusted by healthcare professionals for use in multiple cancer therapies.
This oncology injection is mainly recommended for patients diagnosed with cancers such as small cell lung cancer, testicular cancer, leukemia, lymphoma, and other severe malignant conditions. Doctors may prescribe this medicine alone or as part of combination chemotherapy depending on the patient’s medical condition, stage of cancer, and overall treatment plan.
Chemotherapy medicines like VEPELIEVA are an important part of cancer management because they help reduce the spread of cancer cells and improve the effectiveness of treatment protocols. Since cancer cells multiply rapidly, medicines like Etoposide are specially designed to target these abnormal cells and reduce their growth inside the body.
VEPELIEVA Etoposide Injection IP 100MG is intended strictly for medical use and should only be administered by trained healthcare professionals in clinical settings. Patients are advised not to self-administer this injection. Proper medical monitoring, laboratory testing, and regular health assessments are usually recommended during chemotherapy treatment to ensure patient safety and better treatment response.
This anticancer injection is known for its role in advanced oncology treatment plans and is considered an important chemotherapy medicine in cancer care. With proper medical supervision and supportive care, Etoposide Injection can help improve treatment management in cancer patients.
View Details
Ribavirin Capsules 200mg
RIBALIEVA 200MG (Ribavirin Capsules 200mg) is an antiviral medicine used in the treatment and management of certain viral infections. It contains Ribavirin, a well-known antiviral agent that helps reduce the growth and multiplication of viruses inside the body. This medicine is commonly prescribed by healthcare professionals as part of combination antiviral therapy for chronic viral infections, especially hepatitis-related conditions.
Ribavirin works by interfering with the replication process of viruses, helping reduce viral activity and improving treatment effectiveness. Because of its broad antiviral action, Ribavirin Capsules are widely used in modern antiviral treatment protocols under proper medical supervision.
RIBALIEVA 200MG is generally used in combination with other antiviral medicines rather than as a standalone treatment. Doctors may prescribe this medicine depending on the patient’s viral infection type, medical history, liver condition, and overall health status.
This antiviral capsule is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine is intended for use only under the guidance of qualified healthcare professionals. Patients are advised to follow the prescribed treatment schedule carefully to achieve better treatment outcomes.
Chronic viral infections can affect the liver, immune system, and overall health if not managed properly. Antiviral medicines like Ribavirin play an important role in reducing viral load and supporting long-term disease management. RIBALIEVA 200MG is trusted by healthcare professionals as part of advanced antiviral therapy programs and supportive infection management strategies.
Patients using Ribavirin Capsules may require regular health monitoring, blood tests, and liver function assessments during treatment. Doctors may adjust the dosage depending on treatment response and possible side effects. Proper medical supervision is important throughout the therapy period.
Due to its effectiveness in combination antiviral treatment protocols, RIBALIEVA 200MG is widely used in hospitals, clinics, and healthcare centers involved in infectious disease management and antiviral care.
View Details
